My comment: The personalized medicine revolution is still on the horizon. Being able to evaluate which drug would be best for a patient before trying multiple drugs would be desirable and of great benefit (less cost, less side effects) but insurance payers and guidelines have not yet caught up with this basic science.
39 genetic association with hypertension (HTN) have been identified. This study looked at DNA characteristics (loci/SNPs) associated with HTN and blood pressure response to antihypertensive drugs (specifically the bgereically available atenolol or hydrochlorothiazide. 768 Caucasian hypertensive participants in the Pharmacogenomics Responses of Antihypertensive Responses (PEAR) study were evaluated.
Genotypes of 37 loci were obtained: six reached nominal significance (p<0.05) and 3 were associated with atenolol BP response at p < 0.01.
The genetic score of the HCTZ BP lowering alleles was associated with response to HCTZ (p = 0.0006 for SBP; p = 0.0003 for DBP). Both risk score p values were < 0.01.
These findings suggest selected signals from hypertension GWAS may predict BP response to atenolol and HCTZ when assessed through risk scoring.